Corbus Pharmaceuticals (CRBP)
(Real Time Quote from BATS)
$43.23 USD
+0.54 (1.27%)
Updated May 29, 2024 04:00 PM ET
After-Market: $43.48 +0.25 (0.58%) 4:16 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Corbus Pharmaceuticals Holdings, Inc. [CRBP]
Reports for Purchase
Showing records 41 - 60 ( 60 total )
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
On Track for SSc and CF Data in Summer 2020; Reit Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Phase 3 Lenabasum Topline in SSc Expected Summer 2020, to Pave Way for Transformative Year; Reit Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Looking Ahead to 2020 With Topline Results Anticipated in SSc, CF, and SLE Programs; Reit Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Continued Lenabasum Platform Advancement, Phase 1 Trial for CRB-4001 to Commence by YE19; Reit Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Corbus R-D Day Highlights Platform, SSc and CF Data Expected Summer 2020; Reit Buy and $24PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
We Continue to Interpret the Lenabasum SSc Trial Endpoint Change Positively; Reit Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Cannabis - Where are we and where are we going?
Provider: Edison Investment Research Limited
Analyst: JACOBS M
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Corbus Announces Amended Primary Endpoint in SSc Phase 3 Trial; Improved Swing at Success; Reit Buy and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Recruitment Is on Track as We Wait for Pivotal Phase 3 Results
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Kaken Deal Further Validates Lenabasum''s Promise; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
We Are Resolute: CF Investors Ought to Care About Lenabasum; Initiating With Buy Rating and $24 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J